Alebund Pharmaceuticals Completes Additional Share Buyback; Treasury Stock Rises to 151,400 H Shares

Bulletin Express11-06

Alebund Pharmaceuticals (Jiangsu) Limited reported a minor adjustment to its share capital following an on-market repurchase executed on 06 November 2026. The company bought back 200 H shares at HKD 18.02 each, spending HKD 3,604 in total.

The transaction reduced the number of issued shares (excluding treasury shares) to 235.48 million, down by 0.0001%. Concurrently, treasury shares increased from 151,200 to 151,400, while the aggregate share count remained unchanged at 235.64 million.

The buyback forms part of a mandate approved on 14 August 2026 that authorises repurchases of up to 23.56 million shares. Including the latest purchase, Alebund Pharmaceuticals has repurchased 151,400 H shares under this mandate, representing 0.0643% of the company’s issued share base on the mandate date.

In accordance with Hong Kong listing rules, a 30-day moratorium on new share issues or the sale or transfer of treasury shares is in effect until 06 December 2026. The company confirmed that all repurchases complied with both Hong Kong Stock Exchange regulations and the terms outlined in its July 2026 explanatory statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment